J&J said it will continue to serve the diabetes market through its medical device, pharmaceuticals and consumer businesses.
The transaction will be discussed, J&J said, during its earning call on Oct. 16.
Read more from ROI-NJ:
- J&J accepts $2.1B offer for LifeScan diabetes product business
- J&J announces $2.1B binding offer for its LifeScan unit
- Fortive offers $2.8B for J&J’s sterilization products unit